CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...